Tosi Diego - Institut du Cancer de Montpellier Inserm U1194, Montpellier University

基本信息

浏览量：45

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 90 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Vibostolimab Coformulated with Pembrolizumab (vibo/pembro) for Previously Treated Advanced Mismatch Repair–deficient (dmmr) Endometrial Cancer: Results from Cohort B1 of the Phase 2 KEYVIBE-005 Study

Carlos Rojas,Ferry Eskens,Francois Ghiringhelli,Mustafa Ozguroglu,Christian Caglevic, Mahmut Gumus,Diego Tosi,Julien Grenier,Alejandro Falcon Gonzalez, Andres Arenas,Lucia Gonzalez-Cortijo,Andrew George Robinson,Javier Cuello,Maria C. Bell, Mariusz Kwiatkowski,Mehmet Ali Nahit Sendur,Qi Liu,Tanya Elizabeth Keenan,Jane Anne Healy,Robin Guo

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

BreAK CRC, a First-in-human Phase I/II Trial of STC-1010, a New Allogenic Cancer Vaccine for Advanced or Metastatic Unresectable Colorectal Cancer

Benoit You,Antoine Italiano,Antoine Hollebecque,Ahmad Awada, Francesco Sclafani,Diego Tosi,Philippe Alexandre Cassier,Eric Christenson,David Tougeron,David P. Prime Erol,Corinne Tortorelli,Benoit Pinteur,Lionel Chalus,George Alzeeb,Paul Bravetti,Francois Ghiringhelli

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

The Hippo Pathway Terminal Effector TAZ/WWTR1 Mediates Oxaliplatin Sensitivity in P53 Proficient Colon Cancer Cells

Věra Slaninová,Lisa Heron-Milhavet,Mathilde Robin,Laura Jeanson,Adam Aissanou,Diala Kantar,Diego Tosi,Laurent Bréhélin,Céline Gongora,Alexandre Djiane

BMC Cancerno. 1 (2024): 1-18

引用0浏览0WOS引用

25P Patient-reported Outcomes (pros) with Coformulated Vibostolimab/pembrolizumab (vibo/pembro) for Metastatic Cervical Cancer (CC): Results from the KEYVIBE-005 Study

Kan Yonemori, Carlos A. Rojas,Alexandra Leary, C. Le Tourneau,Iwona Ługowska, Özgür Özyılkan,Christian Caglevic,François Ghiringhelli, E.P. Yanez Ruiz, Marloes van Dongen,Ruth Perets, Mahmut Gumus, M. Kwiatkowski,Sun Young Rha,Pamela Salman, Qing Liu, T. Keenan,Allison Martin Nguyen, Puneet K. Singhal,Diego Tosi

ESMO open (2024): 103525-103525

引用0浏览0引用

STING‐ATF3/type I Interferon Crosstalk: A Potential Target to Improve Anti‐tumour Immunity in Chemotherapy‐treated Urothelial Carcinoma

Alexandra Fauvre,Margot Machu, Audrey Merienne,Nadia Vie, Thomas Bessede,Mathilde Robin,Veronique Garambois,Clara Taffoni,Nadine Laguette,Nadine Gervois-Segain,Anne Jarry,Nathalie Labarriere,Yves Allory,Christel Larbouret, Laurent Gros,Diego Tosi,David B Solit,Philippe Pourquier,Nadine Houédé,Celine Gongora

Clinical and Translational Medicineno. 9 (2024): n/a-n/a

引用0浏览0WOS引用

Supplementary Table S1 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer

Eve Combès,Augusto F. Andrade,Diego Tosi,Henri-Alexandre Michaud,Flavie Coquel,Veronique Garambois,Delphine Desigaud,Marta Jarlier,Arnaud Coquelle,Philippe Pasero,Nathalie Bonnefoy,Jerome Moreaux,Pierre Martineau,Maguy Del Rio,Roderick L. Beijersbergen,Nadia Vezzio-Vie,Celine Gongora

crossref（2023）

引用0浏览0引用

Supplementary Figure 2 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer

crossref（2023）

引用0浏览0引用

Supplementary Figure S1 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer

crossref（2023）

引用0浏览0引用

Supplementary Figure 2 from Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer

crossref（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn